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This phase I/II trial examined safety and efficacy of the toll-like receptor 2/6 agonist MALP-2 in combination with gemcitabine in
patients with incompletely resectable pancreas carcinomas. MALP-2 is a toll-like receptor 2/6 agonist, acts as an immunological
adjuvant, and has been described recently to prolong survival in a mouse model of an orthotopic, syngeneic pancreas tumour. Male
and female patients with incompletely resectable pancreas carcinomas were eligible while those with R0 or R1 resections or with
peritoneal carcinosis were excluded. Ten patients were injected intratumourally during surgery with 20–30mg MALP-2 followed by
postoperative chemotherapy. Samples were taken from peripheral blood and wound secretion, and assayed for cell content, cytokine
and CRP levels, and NK activity. An MALP-2 dose of 20mg was well tolerated. Clear signs of local MALP-2 effects were presented by
the influx of lymphocytes and monocytes in wound secretions, and abolishment of inhibition of NK activity. The actual mean survival
is 17.174.2 months; the median survival being 9.3 months. Two patients are still alive after 31 months. Up to 20mg MALP-2 was well
tolerated, and no systemic side effects were noted. The mean survival of 17.1 months is remarkably high.
British Journal of Cancer (2007) 97, 598–604. doi:10.1038/sj.bjc.6603903 www.bjcancer.com
Published online 31 July 2007
& 2007 Cancer Research UK
Keywords: pancreatic adenocarcinoma; toll-like receptor; immunotherapy
                                           
Carcinoma of the exocrine pancreas has an extremely poor
prognosis. The 5-year survival rate is o1% with a median survival
of 4–6 months. Even with radical curative surgery and adjuvant
chemotherapy (CT) the 5-year survival is at best 25% in specialised
centres (Neoptolemos et al, 2001). After palliative surgical
intervention, the 1-year survival is 20% and the 5-year survival
rate is 3% (Koslowsky et al, 2001; Raraty et al, 2002). The standard
palliative treatment with gemcitabine results in a median survival
of 5.7 months (Burris et al, 1997). Recently, data from a phase III
trial showed that treatment with gemcitabine plus capecitabine
increased survival to 7.4 months (Cunningham et al, 2005).
Intraoperative radiotherapy (IORT) is another therapeutic
strategy in patients with locally advanced disease. It involves
delivery of high doses of irradiation to the pancreas and to the
surgical bed following pancreatic resection, while uninvolved and
dose-limiting tissues are displaced. Ihse et al (2005) reported a
median survival of 7 months from 37 patients with advanced
pancreatic carcinoma.O’Connor et al(2005) reported a median
survival of 11 months for 24 patients who underwent surgical
bypass and IORT.
Immunotherapy could be another strategy for cancer treatment.
General barriers to successful tumour vaccination consist of
various escape mechanisms developed by tumour cells to avoid
immune attack. Malignant cells evade immunosuppression by
downregulating intrinsic immunogenicity (Bissell and Radisky,
2001), or by induction of tolerance or anergy, in particular of
dendritic cells (DC) (Wittke et al, 1999). Jaffee et al(1998) showed
in preclinical studies with murine tumour models that tumour cell
vaccines engineered to secrete GM-CSF in a paracrine fashion elicit
systemic immune responses capable of eliminating small amounts
of established pancreatic tumour. Safety and anti-tumour im-
munity of this approach was recently demonstrated in a phase I
and a phase II trial (Jaffee et al, 2001; Laheru et al, 2005).
The purpose of our study was to define the toxicity and efficacy
of the toll-like receptor 2/6 agonist MALP-2 (Morr et al, 2002) in
combination with gemcitabine for the treatment of unresectable
pancreas carcinoma. The rationale of this approach is based on
the ability of MALP-2 to (1) act as an immunological adjuvant
(Rharbaoui et al, 2002), (2) activate murine as well as human DC
to express co-stimulatory molecules (Weigt et al, 2003), (3) induce
a T-helper 1 type of response (Wittke et al, 1999) and, most
importantly, prolong survival in a mouse model of an orthotopic,
syngeneic pancreas tumour (Schneider et al, 2003). In these
experiments MALP-2 was administered by intratumoural injection,
alone, or in combination with systemic gemcitabine. We
interpreted the beneficial effects were due to immune activation,
as we observed an increase in the expression of co-stimulatory
molecules on lymphocytes, and cytotoxic T and NK cells
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sinfiltrating the tumour. For technical reasons, the pharmacokinetic
data were not evaluated in this trial. However, animal experiments
in diabetic mice showed disappearance of MALP-2 activity from
the skin with a half time of about 20h (Deiters et al, 2004). MALP-
2 is degraded by two different mechanism in inflamed tissue: (1)
de-esterification and (2) oxidation of the thioester bridge
(Mu ¨hlradt et al, 1998).
MATERIALS AND METHODS
Design and setting
Patients who underwent laparotomy with incomplete or no
resection of pancreatic adenocarcinoma were treated intraopera-
tively with 20–30mg MALP-2. The later was administered
intratumourally after careful aspiration to prevent intravasal
injection. The maximum injected volume was 750ml distributed
in up to eight single injections, to cover the whole tumour. The
dose of MALP-2 was escalated in 5mg steps after treatment of two
patients until CTC4grade 2 was achieved. A postoperative CT
with gemcitabine administered in an outpatient setting followed
as soon as possible. Gemcitabine was given at a dosage of
1000mgm
 2 on days 1, 8, 15, 22, 29, 36, and 43, with a break on
day 50 followed by 4-week cycles over 3 weeks of therapy duration.
Patients with prior CT and/or radiotherapy (RT) were included in
the trial.
Participants
In phase I/II trial of this study, patients with attempted surgical
resection were selected while those with R0 or R1 resections were
excluded as there are well-known standard therapies available. In
addition, patients with peritoneal carcinosis were not considered,
because targeted injection is not possible in disseminated disease.
Patients with suspected hypersensitivity to TNF-a were excluded as
well.
Male and female patients with pancreatic adenocarcinoma were
eligible for participation in the study. Patients whose carcinomas
were unlikely to be completely resectable upon medical examina-
tion were informed about this study. The nature, scope, and
possible consequences of the trial were explained by a physician,
and informed consent was obtained from each patient in oral and
written form before inclusion in the trial. The final protocol was
approved by the ethics committee of the University of Heidelberg,
Medical School (L-239/2003). The protocol has been published in
October 2003 on www.kimt.de with the number HD239. The first
patient was enrolled in April 2004.
MALP-2
The biologically active R-stereoisomer of MALP-2 was synthesised
and HPLC-purified as described (Morr et al, 2002). A stock of
1mgml
 1 MALP-2 solution was prepared in pyrogen-free water
containing 33% vv
 1 2-propanol, and the exact content was
determined by amino acid and fatty acid analysis. MALP-2
solutions for injections were then made up to a final concentration
of 40mlml
 1 in water with 10%, vv
 1 2-propanol and 2% wtv
 1
human serum albumin 20%. The biological activity of MALP-2 was
tested by nitric oxide release as described elsewhere (Mu ¨hlradt
et al, 1997). Each lot of MALP-2 was tested for sterility at the
Department of Hygienic, University of Heidelberg. Endotoxin
contamination was examined by two methods: (1) LAL-assay at
the Department of Hygienic, University of Heidelberg (2) a very
sensitive nitric oxide release assay with TLR-2 knockout mice.
Cells from these animals did not react to the MALP, as MALP uses
TLR 2/6 as receptor, whereas LPS uses TLR 4. The test would have
indicated even small amounts of LPS if it had been present.
Immunomonitoring
Peripheral blood mononuclear cells (PBMC) were isolated and
stored frozen at  801C. Wound secretion was obtained either
directly during the operation or later on from EasyFlow drainage.
During the operation, wound secretion was obtained by a syringe
inserted close to the injection site. Afterwards, EasyFlow drainage
was placed close to the tumour, collected wound secretion was
taken from the drainage at the indicated time points and receptacle
was emptied. Blood was taken from patients shortly before
MALP-2 injection and after 1, 6, and 16h and 3 days following
the injection. Blood and wound secretion samples from untreated
patients with pancreatic adenocarcinoma who gave their informed
consent were obtained as controls.
Leucocytes were analysed after the lysis of erythrocytes, by flow
cytometry on an EPICS XL (Coulter, Krefeld, Germany) as
previously described (Schmidt et al, 2007). Serum cytokine levels
were determined using FlowCytomix technology (Bender Med
Systems, Vienna, Austria) (Schmidt et al, 2007). The Human
Granzyme B ELISpot Set was used according to the manufacturer’s
instructions (BD, Heidelberg, Germany) with 400000 PBMCs per
well and stimulation with 100mgml
 1 MUC-1, 100Uml
 1 CA19.9
(Merck, Schwalbach, Germany), or medium as a control. Spots
were counted after 24h of incubation. Deep-frozen PBL were used
for the NK cytotoxicity assay against K562 cells in a standard
chromium release assay (Schmidt et al, 2007).
Statistical analysis
Mann–Whitney U-test, Pearson’s correlation, log-rank test and
paired t-test on SPSS 11.5 were used to analyse statistical
significance where appropriate. A P-value o0.05 was considered
as significant.
RESULTS
Patients
Ten patients, four females and six males, were included in this
study and all received MALP-2. Median age was 68.5 years. Five
patients were R2 resected, one underwent hepatojejunostomy plus
gastrojejunostomy, three hepatojejunostomy, and one underwent
explorative laparotomy. Four patients had received neither pre-
nor intraoperative RT nor CT, two had undergone IORT, two IORT
and RT preoperatively, and two had received IORT and radio-
chemotherapy (RCT) before surgery, and two had received CT,
RCT, and IORT before surgery. They were treated postoperatively
with gemcitabine, or received additional RCT. One patient was
treated with hyperthermia on his own will (see Table 1). All
patients had T3 adenocarcinomas, 50% had positive lymph nodes,
and median age was 69 years.
Three patients received no postoperative therapy, one of them
died on day 54 because of rapid progression of the disease.
Another patient died on day 49 due to postoperative complica-
tions, and one patient did not recover from his myocardial
infarction 3 days after surgery and was therefore not further
treated.
Toxicity
An MALP-2 dose of 20mg given to five patients was generally well
tolerated. Neither vital signs nor routine laboratory data differed
from those of untreated control patients after surgery of pancreatic
carcinoma. Serious adverse events (SAE) were recorded in two out
of three patients treated with 25mg MALP-2. Patient 4 with a
known history of myocardial infarction suffered a myocardial
infarction 3 days following surgery and concomitant MALP-2
injection. A correlation of this SAE with MALP-2 treatment was
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sdefined as ‘not assessable’. Patient 5 suffered from three episodes
of cardiac arrest 18h post-intraoperative MALP-2 injection. He
was successfully resuscitated, and a temporary cardiac pacemaker
was implanted. The patient completely recovered. Patient 6 was
treated with 30mg MALP-2 and 15min after injection she became
hypovolemic and required volume resuscitation and vasopressors.
The patient recovered within 2 days. Retrospectively, accidental
intravenous injection of MALP-2 could not be rigorously excluded
as aspiration was not performed in this patient to explain the
early shock-like symptoms. However, CRP levels, that should be
indicative of a systemic MALP-2 reaction, were lower than in
control patients (see also below). Patient 6 developed an
abdominal sepsis with infected ascites 2 weeks after surgery. She
died of septic multi-organ failure on day 49. In patient 7, who
received 30mg MALP-2 as well, no side effects were noticed.
Clinical outcome
Although our study was a phase I/II trial primarily focusing on
toxicity, dose escalation and immuno-monitoring, the clinical
outcome was a secondary objective. The mean survival is 17.174.2
months (CI 8.9; 25.3); the median survival was 9.3 months. Two
patients were still alive after 31 months (Figure 1). There were no
significant differences in survival rates of patients with regard to
the different surgical approaches applied (R2 resection vs palliative
surgery), intraoperative strategies (IORT vs no RT), or the MALP-2
dosage. No metastases were reported during follow-up.
Laboratory parameters
The routine laboratory parameters revealed no conspicuous
abnormalities, except the CRP values. When we grouped MALP-
2-treated patients in terms of survival time into responders
(survival49 months) and non-responders (survival o9 months),
an interesting pattern became apparent: during the first 4 days
after surgery/MALP-2 treatment, CRP levels in responders were
significantly higher than in non-responders (survival o9 months;
Po0.001) or control patients (Po0.035). On the other hand, there
was no significant difference between non-responders and control
patients (Po0.8). After day 5 all groups became identical
(Figure 2).
NK cell–mediated cytotoxicity
Upon monitoring the NK cell activity against K562 targets before
and after surgery, the control group, who had not received
MALP-2, showed a suppression of NK activity on day 3 as
compared to values from samples taken during surgery. This effect
was overcome in the MALP-2-treated patients. Thus, NK activity
on day 3 was significantly higher in MALP-2 patients than in
control patients (Po0.03; Figure 3A and B). This observation,
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Figure 1 Overall survival of patients. Ten patients were treated with
various doses of MALP-2.
Table 1 Patients’ Characteristics
Age Gender
Dosage
(lg)
Type of
operation
Preoperative
therapy
Postoperative
therapy
Side effects (CTC
grade)/relationship
OS
(months) Status
1 63 M 20 R2 CT, RCT, IORT CT — 38.0 Alive
7 67 M 30 Palliative IORT RCT — 31.3 Alive
5 63 M 25 Palliative CT, RCT, IORT CT Asystole (3), possible 29.3 Died
3 74 M 20 R2 — CT — 20.4 Died
8 69 F 20 Palliative IORT CT — 17.4 Died
10 68 M 20 Palliative — Hyper-thermia — 9.3 Died
2 37 F 20 R2 — CT — 9.0 Died
4 73 M 25 R2 RCT, IORT — Myocardial infarction
(4), not assessable
6.5 Died
9 69 F 25 Palliative — — — 1.8 Died
6 69 F 30 R2 RCT, IORT — Endotoxin-like shock
(4), probably
1.6 Died
Abbreviations: CT, chemotherapy; CTC, common toxicity criteria; F, female; IORT, intraoperative radiotherapy; M, male; OS, overall survival; RCT, radiochemotherapy.
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swhen supported by more patient histories, may become of
prognostic value.
Leucocyte subpopulations in PBL and wound secretion
Since MALP-2 is known to induce chemokines and, upon local
administration, infiltration of leucocytes (Deiters and Mu ¨hlradt,
1999), we wished to know whether MALP-2 in the setting of this
study could act systemically by influencing the composition of
PBL, or whether any effects would be topically restricted and
become apparent upon analysis of the wound secretions. Since,
there were only small if any effects on the PBL composition,
significant changes were seen in the leucocytes from the wound
secretion. Lymphocytes as well as monocytes started to increase in
number 6h after MALP-2 treatment. Leucocyte subpopulations in
the wound secretion were recorded as percentage as they were
heavily contaminated with cells from connective and other tissues.
T cells, among them CD45ROþ memory T cells, peaked at 6h,
whereas monocytes showed a maximum value on day 1 and
expressed activated CD40þ ones later (Figure 4A–D).
Granzyme B ELISpot and cytokine profiles
Data generated from Granzyme B ELISpot and from cytokine
profiling in the serum resulted in no significant difference between
control and MALP-2 patients. However, IL-6 levels were high in
the wound secretion and in serum and increased with time also in
the untreated populations. In MALP-2-treated patients, this effect
was more pronounced and appeared earlier (Figure 5A and B).
DISCUSSION
Carcinomas of the exocrine pancreas have an extremely poor
prognosis. Radio- and chemotherapy are not very efficient even
after attempted radical surgery. In this respect, combination with
immunotherapy could be another strategy for cancer treatment. As
pancreatic carcinomas lack well-characterised tumour antigens,
unspecific immunotherapy might be a treatment option. Immuno-
modulators such as chemokines or adjuvants act by inducing
cytokine secretion from monocytes or macrophages. They lead to a
Th1-skew and cell-mediated immunity. Adjuvants can be the
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Figure 3 (A and B) Cytotoxicity of peripheral blood lymphocytes.
Peripheral blood mononuclear cells were thawed 1 day before analysis.
Monocytes were removed by plastic adherence. Cytotoxic activity was
determined in a standard chromium release assay against the classical NK
cell target K562. Data are shown as mean from 10 MALP-2 patients (A)
and 4 control patients (B). Data are shown as mean7s.e.m.
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sdanger signals that are necessary to stimulate DC for optimal
antigen presentation and stimulation of effector cells. They may
help to link the innate and adaptive immune system.
Tumour-suppressive effects of lipopeptides have been described
previously (Fidler et al, 1989; Utsugi et al, 1991; Xie et al, 1995,
1996; Xie and Fidler, 1998; Bruns et al, 2000; Galanos et al, 2000;
Shinohara et al, 2000). Recently, we reported the treatment with
MALP-2 applied to an orthotopic pancreatic carcinoma mice
model. The MALP-2-treated animals showed a significantly
prolonged survival, especially in combination with CT. Further-
more, a strong immune response could be observed. Tumours of
treated mice were infiltrated with NK and T cells and a Th1 shift
was detected. The signal transduction cascade activated by MALP-
2 is as well described as the patterns of mediators secreted after
injection of the lipopeptide. MALP-2 binds to TLR-2 and TLR-6 on
monocytes and other cells. This results in the activation of NF-kB
and other transcription factors, as well as the release of pro-
inflammatory cytokines (Sacht et al, 1998; Deiters and Mu ¨hlradt,
1999; Kaufmann et al, 1999). Doses up to 1mg were given s.c. into
the wound edge applied by punch biopsy to volunteers undergoing
a phase I study about MALP-2 application to heal chronic wounds.
Except for erythemas there were no side effects.
After deciding to investigate this approach in a clinical study, we
were faced with several obstacles. One of these was related to the
order of administering the CT and immunotherapy. Although
the commonly used regimen is to start with CT followed by
immunotherapy, we could only start with immunotherapy
followed by CT due to some technical reasons. On the other hand,
we presume that induction of necrosis by surgical intervention also
results in the release of immunogens, which could then be taken up
by MALP-2-activated antigen-presenting cells.
It is well known that surgery results in immune suppression
(Menger and Vollmar, 2004). Furthermore, there is strong evidence
from animal data that a whole host of agents that broadly stimulate
the immune system are effective in reducing significantly the
incidence of tumour metastases and the growth of tumours after
surgery. In theory, perioperative immune upregulation would
provide the patient with the ability to kill tumour cells immediately
following surgery through specific and innate immune responses.
We observed an immune-suppressive effect in control patients
regarding NK cell–mediated cytotoxicity, which was overcome in
MALP-2-treated patients. This might be one explanation for the
lowered incidence of metastasis that has been observed in our
patients. Indeed, MALP-2 by itself features an anti-metastatic effect
in animal experiments (Shingu et al, 2003).
The immunomonitoring, as the crucial part of this phase I/II
trial, was restricted by the number of specimen we could sample
without causing too much inconvenience to our patients and the
number of assays we could perform. Since the study investigates
an unspecific immunostimulants, and since there are only few
potential target antigens described for pancreatic carcinomas,
assays like tetramer analysis or peptide-specific ELISpots were not
feasible. It was also not possible to establish tumour cell lines from
the majority of patients as a source of autologous antigen or as a
target in cytotoxicity assays (Keilholz et al, 2002). Another general
issue in immunomonitoring is the fact that in most cases it is only
possible to look for activated cells in the periphery and not in the
tumour. We tried to solve these problems by investigating
unspecific responses as NK cell mediated cytotoxicity, immuno-
phenotyping, and cytokine serum levels in peripheral blood and
in the wound secretion. For the detection of antigen-specific cells
we performed ELISpots with whole-tumour antigens (CA 19.9 and
MUC-1) which are expressed in tumour cells of 485% of all
patients. The time points of blood withdrawal were restricted due
to fast-track surgery.
In general, we underestimated the effect of surgical procedures
on the immune system and the problems ensued regarding the
immunomonitoring. Here, the presence of unaffected NK cell-
mediated cytotoxicity in MALP-2 patients is to strengthen.
Moreover, an increase in memory T cells and CD40 expression
on monocytes, particularly in the wound secretion, was detected.
No significant changes in the PBL were noted. Based on this
observation, it seems that MALP-2 effects are predominantly local.
Unfortunately, we were not able to draw samples in a long enough
period of time after intervention (414 days) for an adequate
detection of antigen-specific T cells.
In addition, the patterns of CRP, IL-6, and TNF-a levels were
unpredicted. CRP is produced almost exclusively by liver
hepatocytes as part of the acute-phase response to IL-6, TNF-a,
and IL-1b originating at the site of inflammation. Preoperative and
postoperative CRP levels of 410mgl
 1 are independent indicators
predictive of poor prognosis of patients with pancreatic carcinoma
(Jamieson et al, 2005). In contrast, our observations—although
limited—suggest that patients with a high increase of CRP during
the first days had a better outcome than those with the normal
postoperative course. The absence of a change in IL-6 and TNF-a
levels in serum of MALP-2-treated patients was unexpected since
control patients peaked within the first postoperative days. One
possible explanation could be a targeted, local inflammation in
MALP-2 patients that was not detectable in serum or wound
secretion resulting in a noticeable CRP increase. In control patients
we had an untargeted, surgical procedure-related inflammation,
which is measurable in terms of IL-6 and TNF-a in serum and
wound secretion and resulting also in CRP increase.
The following model might explain our observations: (1) MALP-
2 induces local inflammation; (2) surgery and local TNF release
by MALP-2 activated monocytes/macrophages and cause tumour
destruction; (3) leucocytes, including NK cells are directed to the
injection site by the release of chemokines; (4) anergic DC are
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sactivated by MALP-2 to mature (Weigt et al, 2003). Such DC could
take up apoptotic or necrotic tumour cells and prime lymphocytes;
(5) these lymphocytes can infiltrate the tumour, as shown in the
animal model (infiltration with NK cells and T cells); and (6)
MALP-2 prevents metastases (Shingu et al, 2003, unpublished data).
Although the cohort is too small for any final conclusions, it
seems that the patients had a benefit from the regimen. Pre-, intra-
and postoperative therapies are not comparable between the
patients but the data did not give the impression that any
particular treatment was responsible for a better outcome. The
mean survival of 17.174.2 months (CI 8.9; 25.3) was surprisingly
high. Interestingly, there were no significant differences either
between patients who had an R2 resection (R0–R1 resection
intended) or palliative surgery, with or without IORT, nor between
groups treated with variant MALP doses. Since no toxicity was
observed in the patients group treated with up to 20mg MALP-2,
we recommend to use this dosage in further trials.
In conclusion, MALP-2 in dosages up to 20mg is not associated
with side effects. Although the immunosuppressive impact of
invasive manipulations compromise immunomonitoring, some
interesting activating and anti-immunosuppressive effects were
detected. The clinical outcome with a mean survival of 17.1 months
is remarkably high. Further studies are required to evaluate the
clinical and immunological impact of MALP-2.
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